Related Experiment Video
Updated: May 3, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
[Treatment of Behçet's disease]
C Comarmond1, B Wechsler1, P Cacoub1
1Service de médecine interne et d'immunologie clinique, centre de référence des maladies autoimmunes rares, DHU i2B, inflammation, immunopathologie, biothérapie, université Pierre-et-Marie-Curie, groupe hospitalier Pitié-Salpêtrière, AP-HP, Paris 6, Paris, France.
Insights
Behçet's disease (BD) is a complex vasculitis requiring tailored treatment. Future therapies may offer targeted approaches for refractory cases, improving patient outcomes.
Area of Science:
- Rheumatology
- Immunology
- Vascular Medicine
Background:
- Behçet's disease (BD) is a systemic vasculitis with diverse clinical manifestations.
- Current treatments include colchicine, NSAIDs, corticosteroids, and immunosuppressants for severe cases.
- Refractory disease, relapses, and organ damage remain significant challenges in BD management.
Purpose of the Study:
- To review the current understanding of Behçet's disease pathogenesis.
- To explore emerging therapeutic strategies targeting specific pathways in BD.
- To discuss the potential of novel immunomodulatory and targeted therapies.
Main Methods:
- Literature review of Behçet's disease pathogenesis and treatment.
- Analysis of recent advancements in understanding BD mechanisms.
- Evaluation of novel therapeutic targets and drug development.
Main Results:
- Pathogenic mechanisms of BD are increasingly understood.
- Immunomodulatory and targeted therapies show promise for specific pathways.
- These novel approaches may offer alternatives to current non-specific immunosuppressants.
Conclusions:
- Understanding BD pathogenesis is key to developing targeted therapies.
- Emerging immunomodulatory drugs offer potential for specific pathway interference.
- Novel targeted immunosuppressive therapies represent a future direction for BD treatment.
Abstract:
Behçet's disease (BD) is a systemic large-vessel vasculitis characterized by a wide clinical spectrum including recurrent oral and genital ulcerations, uveitis, vascular, neurological, articular, and gastrointestinal manifestations. Therapeutic management of BD depends on the clinical presentation and organ involved. Although colchicine, non-steroidal anti-inflammatory agents and topical treatments with corticosteroids are often sufficient for mucocutaneous and joint involvement, a more aggressive approach with immunosuppressive agents is warranted for severe manifestations such as posterior uveitis, retinal vasculitis, vascular, neurological and gastrointestinal involvement. However, some patients still have refractory disease, relapses, sight threatening eye disease, or irreversible organ damage. Recent improvements in the understanding of the pathogenic mechanisms have led to the identification of potential targets and future therapies for BD. In contrast to current non-specific immunosuppressive agents, the emergence of immunomodulatory drugs provides the possibility of interfering with specific pathogenic pathways. Novel targeted immunosuppressive therapies might be used in the future for BD.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents